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Abstract
Background: Outcomes for pediatric solid tumors have significantly improved over the last 30 years. However, much of this
improvement is due to improved outcome for patients with localized disease. Here we evaluate overall survival (OS) for
pediatric patients with metastatic disease over the last 40 years.
Procedure: The United States Surveillance, Epidemiology, and End Results (SEER) database was used to conduct this study.
Patients diagnosed between 0 and 18 years of age with metastatic Ewings sarcoma, neuroblastoma, osteosarcoma,
rhabdomyosarcoma or Wilms tumor were included in the analysis.
Results: 3,009 patients diagnosed between 1973–2010 met inclusion criteria for analysis. OS at 10 years for patients
diagnosed between 1973–1979, 1980–1989, 1990–1999 and 2000–2010 was 28.3%, 37.2%, 44.7% and 49.3%, respectively
(p,0.001). For patients diagnosed between 2000–2010, 10-year OS for patients with Ewing sarcoma, neuroblastoma,
osteosarcoma, rhabdomyosarcoma and Wilms tumor was 30.6%, 54.4%, 29.3%, 27.5%, and 76.6%, respectively, as compared
to 13.8%, 25.1%, 13.6%, 17.9% and 57.1%, respectively, for patients diagnosed between 1973–1979. OS for neuroblastoma
significantly increased with each decade. For patients with osteosarcoma and Ewing sarcoma, there was no improvement in
OS over the last two decades. There was no improvement in outcome for patients with rhabdomyosarcoma or Wilms tumor
over the last 30 years.
Conclusions: OS for pediatric patients with metastatic solid tumors has significantly improved since the 1970s. However,
outcome has changed little for some malignancies in the last 20–30 years. These data underscore the importance of
continued collaboration and studies to improve outcome for these patients.
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There has clearly been an effort to improve outcome for
pediatric patients with metastatic disease. Using National Cancer
Institute’s Surveillance, Epidemiology, and End Results (SEER)
registry, we evaluated outcome for patients less than 19 years of
age diagnosed with metastatic Ewing sarcoma, neuroblastoma,
osteosarcoma, rhabdomyosarcoma and Wilms tumor between
1973–2010.

Introduction
With advances in medical therapy, survival for pediatric solid
tumors has significantly improved over the past 30 years. This
improvement has been achieved through improvements in efficacy
and reductions in toxicity of multi-modal therapy that includes
chemotherapy, surgery and/or radiation therapy. While patients
with localized disease have experienced the largest improvement
in outcome, improvement in survival for patients with metastatic
disease has been more limited [1–6].
The approach to treating pediatric patients with metastatic
disease is unique from that of adults in that treatment is often
approached with curative intent with the use of intensive therapy.
Through pediatric cooperative groups in both the United States
and abroad, numerous clinical trials including phase III randomized trials, have been completed or are currently being conducted.
These studies not only allow for the inclusion of patients with
metastatic disease but, in many cases, are also specifically designed
for this subset of patients [7–12].
PLOS ONE | www.plosone.org

Materials and Methods
The United States Surveillance, Epidemiology, and End Results
(SEER) database was used to conduct this study [13]. This
research was determined to be exempt from IRB oversight by the
IRB at Washington University School of Medicine. SEER*Stat
version 8.1.2 (Surveillance Research Program, National Cancer
Institute, Bethesda, MD, USA) was used to compile data from the
SEER public-use database. Patients diagnosed between 1973–
2010 provided by 18 registries were identified. Patients between 0
and 18 years of age diagnosed with metastatic disease from the
1

July 2014 | Volume 9 | Issue 7 | e100396

Outcome for Children with Metastatic Disease

following malignancies were included in the study: Ewing
sarcoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma and
Wilms tumor. The following International Classification for
Childhood Cancer site recode extended ICD-0-3 histology codes
were included: 8900–8902, 8910, 8912, 8920, 8921, 8960, 9180–
9183, 9186, 9192, 9193, 9260 and 9500. Patients with a prior
diagnosis of cancer were excluded from analysis. Patient demographic information including age, race, gender, year of diagnosis,
follow-up time, vital status at last follow-up and cause of death
were collected. Overall survival (OS) was evaluated using the
Kaplan-Meier method. Hazard ratios (HRs) for risk of mortality
were calculated comparing patients by decade of diagnosis using
the Cox proportional hazards model. Statistical analysis was
performed using SAS version 9.2 (Cary, NC).

Figure 1. HRs for risk of mortality OS for each tumor type over
time are presented in Table 2. For patients with Ewing sarcoma,
10-year OS for patients diagnosed between 2000–2010 was 30.6%
as compared to 13.8% for patients diagnosed between 1973–1979.
Patients diagnosed between 1980–1989 experienced worse OS
compared to patients diagnosed between 2000–2010 (HR = 1.48,
95% CI 1.01–2.17); however, there was no significant difference in
OS for patients diagnosed in the 19909s versus 2000–2010
(HR = 0.94, 95% CI 0.65–1.37).
For patients with neuroblastoma, OS significantly increased
during each decade (Figure 1). When compared to patients
diagnosed between 2000–2010, HRs for risk of mortality were
significantly worse for each previous decade (Table 2). OS at
10 years for patients diagnosed between 1973–1979, 1980–1989,
1990–1999 and 2000–2010 were 25.1%, 32.9%, 43.5% and
54.4%, respectively (p,0.001). For neuroblastoma patients greater
than or equal to 2 years old at diagnosis there is also steady
significant improvement in outcome over time. In the 1970s and
1980s, 10-year OS for these older children was 2.0% and 10.9%,
respectively. By the 1990s, 10-year OS increased to 26.8% and for
patients diagnosed after 1999 10-year OS was 38.9%. Patients
diagnosed prior the age of two years diagnosed between 1973–
1979, 1980–1989, 1990–1999 and 2000–2010 experienced 10year overall-survival of 42.9%, 52.7%, 59.1%, and 71.5%,
respectively (p,0.001). For patients two years of age or older,
OS between 1973–1979, 1980–1989, 1990–1999 and 2000–2010
was 2.0%,10.9%, 26.8%, and 38.9%, respectively (p,0.001). HRs
for risk of mortality for neuroblastoma patients stratified by age
less than 2 years of age are presented in Table 2.
OS at 10 years for osteosarcoma patients with metastatic disease
diagnosed between 1973–1979, 1980–1989, 1990–1999 and
2000–2010 were 13.6%, 5.1%, 23.9% and 29.3%, respectively.
Patients diagnosed between 2000–2010 experience improved
survival over patients diagnosed in the 1970s and 1980s; however,

Results
A total of 10,938 pediatric patients with Ewing sarcoma,
neuroblastoma, osteosarcoma, rhabdomyosarcoma, and Wilms
tumor were identified. Of these patients, 3,009 patients had
metastatic disease at diagnosis and met inclusion criteria for
analysis. Patient demographic information is presented in Table 1.
Overall, 27.5% of patients were found to have metastatic disease
at diagnosis. The percentage of patients presenting with metastatic
disease did not significantly change over time ranging from 26% in
the 1970s to 27% in the 2000s. The rate of metastatic disease was
22.3% for Ewing sarcoma, 49.1% for neuroblastoma, 22.5% for
rhabdomyosarcoma, 13.1% for osteosarcoma and 20.4% for
Wilms tumor. However, the number of children with metastatic
disease included in the SEER registry increased with each decade.
This is a reflection of the increasing number of SEER registry sites.
In the 19709s there were 9 SEER registry sites and by the end of
this study period, there were 18 SEER registry sites.
Median follow-up of all patients was 2.3 years (range 0–
37.8 years). OS over time for each tumor type is presented in
Table 1. Patient Information.

All Patients
N(%)

Ewing
Sarcoma

Neuroblastoma

Osteosarcoma

habdomyosarcoma

Wilms
Tumor

Patients N (%)

3009

289 (9.6)

1478 (49.1)

266 (8.8)

441 (14.7)

535 (17.8)

Mean Age in
Years at
Diagnosis
(range)

5.6 (0–18)

12.7 (0–18)

2.4 (0–18)

13.3 (2–18)

9.0 (0–18)

4.1 (0–17)

Gender
Male

1681 (55.9)

171 (59.2)

839 (56.8)

169 (63.5)

257 (58.3)

245 (45.8)

Female

1328 (44.1)

118 (40.8)

639 (43.2)

97 (36.5)

184 (41.7)

290 (54.2)

White

2359 (78.4)

263 (91.0)

1137 (76.9)

199 (74.8)

335 (76.0)

425 (79.4)

Black

297 (13.2)

6 (2.1)

186 (12.6)

43 (16.2)

76 (17.2)

86 (16.1)

Other

234 (7.8)

20 (6.9)

140 (9.5)

23 (8.6)

29 (6.6)

22 (4.1)

Unknown

19 (0.6)

0

15 (1.0)

1 (0.4)

1 (0.2)

2 (0.4)

1973–1979

248 (8.2)

32 (11.1)

117 (7.9)

22 (8.3)

28 (6.3)

49 (9.2)

1980–1989

458 (15.2)

47 (16.3)

215 (14.5)

39 (14.7)

64 (14.5)

93 (17.4)

1990–1999

653 (21.7)

61 (21.1)

319 (21.6)

71 (26.7)

86 (19.5)

116 (21.7)

2000–2010

1650 (54.8)

149 (51.6)

827 (56.0)

134 (50.4)

263 (59.6)

277 (51.8)

Race

Year of Diagnosis

Abbreviations: N = number.
doi:10.1371/journal.pone.0100396.t001

PLOS ONE | www.plosone.org
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Figure 1. Overall survival based on tumor type.
doi:10.1371/journal.pone.0100396.g001

an increased risk of mortality compared to patients diagnosed
between 2000–2010 (HR = 2.11, 95% CI 1.28–3.50). However,
there has been no significant increase in survival since that time.

there has been no significant improvement in outcome compared
to patients treated in the 1990s.
For patients with metastatic rhabdomyosarcoma, 10-year OS
for the past 30 years was nearly identical. OS at 10 years for
patients diagnosed between 1980–1989, 1990–1999 and 2000–
2010 was 29.7%, 29.1% and 27.5%, respectively. However,
patients diagnosed between 2000–2010 did experience a significant increase in survival as compared to patients diagnosed
between 1973–1979 (HR = 2.01, 95% CI 1.31–3.08). For patients
with embryonal rhabdomyosarcoma (n = 192), OS at 10 years for
patients diagnosed between 1973–1979, 1980–1989, 1990–1999,
2000–2010 was 27.8%, 37.2%, 35.0% and 40.5%, respectively.
There were few patients with known alveolar histology diagnosed
prior to 2000 (n = 46). For patients diagnosed between 2000–2010
with alveolar histology, 10-year OS was 19.5%.
Wilms tumor patients with metastatic disease diagnosed
between 1973–1979, 1980–1989, 1990–1999 and 2000–2010
experienced 10-year OS of 57.1%, 74.2%, 78.3%, and 76.6%,
respectively. Patients diagnosed between 1973–1979 experienced

PLOS ONE | www.plosone.org

Discussion
Our study shows that despite improvements in survival in
children with metastatic diseases over the past four decades the
outcome in some disease continues to be poor. This is especially
true for patients with bone and soft tissue sarcoma. Rhabdomyosarcoma is the most common soft tissue sarcoma and a quarter of
the patients present with metastatic disease [5]. The Intergroup
Rhabdomyosarcoma Study Group (IRSG) was formed in 1972 to
systematically study the therapy and biology of children with
rhabdomyosarcoma. The first study by the group was IRS-I
(1972–1978) that evaluated the addition of doxorubicin to
vincristine, dactinomycin, and cyclophosphamide (VAC) plus
radiation [14]. The OS of those patients was 20%. The IRS-II
study conducted 1978–1984 evaluated the use of repetitive cycles
of VAC compared to alternating cycles of VAC and vincristine,
3
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Table 2. Hazard Ratio of overall survival for each tumor type based on decade of diagnosis.

P value

10-year Overall Survival (%)

Hazard Ratio of Overall Survival (95% CI)

2000–2010

30.6

1.0

1990–1999

32.2

0.94 (0.65–1.37)

0.75

1980–1989

21.3

1.48 (1.01–2.17)

0.046

1973–1979

13.8

1.84 (1.20–2.83)

0.005

2000–2010

54.4

1.0

1990–1999

43.5

1.45 (1.20–1.74)

,0.0001

1980–1989

32.9

2.15 (1.76–2.63)

,0.0001

1973–1979

25.1

3.08 (2.43–3.92)

,0.0001

2000–2010

71.5

1.0

1990–1999

59.1

1.50 (1.10–2.05)

0.010

1980–1989

52.7

2.00 (1.44–2.79)

,0.0001

1973–1979

42.9

2.76 (1.89–4.01)

,0.0001

Ewing Sarcoma

Neuroblastoma
All Patients

,2 years old

$2 years old
2000–2010

38.9

1.0

1990–1999

26.8

1.41 (1.20–1.91)

0.0005

1980–1989

10.9

3.00 (2.34–3.86)

,0.0001

1973–1979

2.0

6.5 (4.73–9.00)

,0.0001

2000–2010

29.3

1.0

1990–1999

23.9

1.11 (0.78–1.56)

0.57

1980–1989

5.1

2.31 (1.56–3.42)

,0.0001

1973–1979

13.6

2.14 (1.29–3.55)

0.003

2000–2010

27.5

1.0

1990–1999

29.1

1.15 (0.86–1.54)

0.36

1980–1989

29.7

1.00 (0.72–1.40)

0.99

1973–1979

17.9

2.01 (1.31–3.08)

0.001

2000–2010

76.6

1.0

1990–1999

78.3

0.91 (0.56–1.46)

0.91

1980–1989

74.2

1.22 (0.76–1.97)

0.40

1973–1979

57.1

2.11 (1.28–3.50)

0.003

Osteosarcoma

Rhabdomyosarcoma

Wilms Tumor

Abbreviation: CI, Confidence Interval; NR, not yet reached.
doi:10.1371/journal.pone.0100396.t002

between the 1970s to 1980s likely reflects the introduction of IRS
therapy in the 1970s.
Ewing sarcoma represents the second most common soft tissue
sarcoma and the second most common primary bone sarcoma in
children. Although the use of chemotherapy has significantly
improved the outcome of patients with localized disease from an
OS of ,20% to 70–80%, it has not been as effective in patients
with metastatic disease [3]. In the 1960s, patients were treated
with single agent chemotherapy with dismal survival. In the 1970s,
combination chemotherapy was used primarily consisting of VAC
[18]. A large intergroup study was conducted from 1973 to 1978
that randomized patients to VAC with or without doxorubicin
[19]. Patients with localized disease randomized to VAC plus

doxorubicin, and cyclophosphamide [15]. Although the complete
remission rate for those patients was 53% the OS was 26%. The
IRS-III study, conducted between 1984–1991, examined the
addition of cisplatin and etoposide to the previous regimens used
in IRS-II, but failed to improve the survival of patients with group
IV disease with 5-year OS of 27% [16]. Between 1991–1997, IRSIV study evaluated the addition of ifosfamide and etoposide to
VAC and the result also showed no significant improvement in the
3-year event free survival (25%) and 3-year OS (39%) of patients
with group IV disease compared to prior studies [17]. Our findings
in this study reflect the lack of improvement of outcome of those
patients since 1980. The improvement observed in our study

PLOS ONE | www.plosone.org
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doxorubicin had significantly improved survival compared to those
receiving VAC alone. In a landmark study conducted between
1988–1992, patients were randomly assigned to receive 49 weeks
of standard chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin or experimental therapy with
these four drugs alternating with courses of ifosfamide and
etoposide [20]. Although patients with localized disease had
significantly improved survival with the addition of ifosfamide
those with metastatic disease had no benefit with an OS of 22%.
Although the survival of children with localized disease is 73%
[21], the 10-year OS for children diagnosed after 1999 with
metastatic disease in our study remains low at 30.6% with very
limited improvement in survival since the 1980s and 1990s.
Osteosarcoma is the most common primary bone tumor in
children and 15% to 20% of patients present with metastatic
disease. The treatment prior to the 1970s consisted mainly of
surgery with single agent chemotherapy [2]. Meyers et al reported
on a study conducted from 1975 to 1984 using multi-agent
neoadjuvant chemotherapy followed by surgery in children with
metastatic disease but only 11% of the patients survived [22]. The
survival improved in the 1990s to 29% with the addition of
cisplatin to the chemotherapy regimen [10]. These results are
consistent with our observation with survival improving from 10%
in the 1980s to the 31% in the 1990s; however, no significant
improvement has been made since the 1990s.
Although the improvement in patients with soft tissue sarcoma
has been stagnant for the past two to three decades there has been
consistent improvement in the survival in patients with metastatic
neuroblastoma. We observed a significant increase in survival in
every decade since the 1970s. This improvement is likely related to
the intensification of multi-agent chemotherapy and radiation
therapy for these patients [4]. In the 1990s, the introduction of
autologous stem cell transplant (ASCT) and 13-cis-retinoic acid
therapy improved the survival of high risk neuroblastoma patients
[23]. In the past 10 years, survival was further improved with
using immune therapy with Anti-GD2 therapy following ASCT
[24]. Our data shows significant improvement in survival of
patients who are older than 2 years of age at diagnosis as well as
those who are less than 2 years. The survival of those who are less
than 2 years of age is 71.5% while the survival of older patients,
which generally have more biologically aggressive disease, remains
low at 38.9%.
Wilms tumor is the most common renal tumor in children.
Combination chemotherapy with vincristine and actinomycin D
was used as early as the late 1950s and early 1960s [25]. The
National Wilms Tumor Study (NTWS) group was established in
1968 to systematically study therapies for patients with Wilms
tumor. The third NTWS (1979–1986) evaluated the addition of

doxorubicin to the two drug regimen and resulted in an improved
survival of 80% for patients with stage IV favorable histology
disease [26]. The outcome for children with stage IV disease with
diffuse anaplasia has remained poor with an OS of 33% in the
most recent NTWS-5 study [27]. In our analysis the OS of
children with stage IV disease has not improved since 1980s.
It is important to discuss the strengths and weaknesses of these
data. The SEER database offers the unique ability assess outcome
for large numbers of patients with these rare diagnoses who were
treated throughout the United States over the last 40 years.
Limitations to these data are that the SEER database does not
provide details on the use of radiotherapy nor does it provide any
information regarding the chemotherapy employed in the
treatment of these children. Additionally, the SEER database
provides limited biological information. While we are able to
differentiate embryonal versus alveolar histology for many
rhabdomyosarcoma patients, other biological information such
as N-MYC amplification for neuroblastoma patients or anaplastic
histology for Wilms tumor patients were either unavailable or
available for very few patients. Another possible limitation to the
data is the issue of stage migration in more modernly treated
patients. However, we noticed no significant increase in the
percentage of patients diagnosed with metastatic disease in any of
the tumor types over the decades in this study. Our study is a
comprehensive and provocative analysis of the outcome of
children with advanced solid tumors over four decades.
The improvement in outcome for childhood cancer patients is a
testament to the collaborative approach in pediatric oncology
which extends nationally and internationally. However, with the
exception of neuroblastoma, little improvement has been made in
the last 20–30 years for children with metastatic solid tumors.
These results reinforce the importance of continued collaborative
efforts evaluating targeted therapy and further research to
understand the underlying biology of these diseases.

Key Message
Outcome for children with metastatic solid tumors has
significantly improved since the 19709s. However, with the
exception of neuroblastoma, there has been little improvement
in other solid tumors in the last 20–30 years.
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